VESALIO announces the successful initial use of its NeVa VS device in the United States for the treatment of post-aneurysmal subarachnoid hemorrhage (aSAH) cerebral vasospasm.
Vesalio hires Bob Bushok as VP of U.S. Sales and announces high first-pass rates and favorable safety profile in a 145-stroke patient data set for the NeVa™ thrombectomy device with findings published in the journal Interventional Neuroradiology.
MDR certification confirms the company’s commitment of ensuring that their innovative new products meet or exceed these rigorous new standards.
NeVa VS is a patented retrievable nitinol stent specifically designed to treat cerebral vasospasm after aneurysmal rupture.
The first integrated clot micro-filtration technology for stroke thrombectomy patients.
A growing number of European & Middle Eastern doctors and stroke teams are training to #DoTheDropZone with NeVa, a revolutionary thrombectomy device with high first pass rates.
Vesalio, an emerging leader in improving outcomes in patients with vascular occlusion, is proud to announce it has oversubscribed its Class A financing round.
Vesalio announces the completion of enrollment in its FDA IDE clinical study for acute ischemic stroke.
As a board observer and senior advisor to the company, Earl Slee brings extensive medical device innovation and business development expertise.
As an independent board chairman, Mike Kujak will bring expert knowledge and know-how from his years of leadership in the medical device start-up space.
Vesalio announced the start of enrollment in its NATURE study using enVast™, the company’s first thrombectomy system for patients presenting with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention.
Vesalio announces it has successfully secured a Class A financing round. The proceeds will be utilized to support the ongoing US IDE stroke study, establish US infrastructure, expand its innovative product portfolio, and scale international business.
Vesalio announces another key milestone to support entry into the US neurovascular thrombectomy market. Enrollment has commenced in the Vesalio CLEAR acute ischemic stroke FDA IDE clinical trial utilizing the NeVaTM thrombectomy technology platform.
Vesalio announces it has accomplished a key FDA IDE study milestone to support entry into the US neurovascular market. Enrollment in the VITAL 1 clinical trial, assessing the company’s NeVa VS™ technology in the treatment of symptomatic cerebral vasospasm following aneurysmal subarachnoid hemorrhage (aSAH), has been completed.
As our customer and partner list lengthens and our geographical reach expands, we need new team members to join us in our exciting journey. We are looking for clinically oriented commercial profiles driven to deliver results.
Vesalio reports it has obtained an FDA 510k clearance and its 4th CE approval. The FDA 510k indication is for the removal of thrombi in peripheral blood vessels.
Vesalio reports it has surpassed 2,500 clinical cases with the NeVa™ neuro-thrombectomy platform. Physicians have evaluated the Neva Drop Zone™ technology with enthusiasm as it has shown a unique capability of removing the full spectrum of clot types in large vessel occlusion ischemic stroke.
Vesalio announces it has executed additional exclusive distribution agreements in Europe, Latin America, Asia, and the Middle East. With these new partnerships, the NeVa™ Thrombectomy System has gained market coverage in 53 countries.
On January 22 and 23, a diverse group of physicians from 8 different countries trained on new approaches for clot retrieval with the NeVa™ Drop Zone Retrieval Technique at the Vesalio Clot Interaction Workshops that took place at the Vall d’Hebron Research Institute.
Vesalio’s distributor partner in Poland, MedTim sp. A.o.o. was proud to sponsor #AcuteIschemicStroke courses organized in the Warsaw and Masovian Voivodship hospitals. During the courses (December 6-7, 2019 and January 17-18, 2020), our Polish team presented #NeVa to physicians #thrombectomy and provided hands-on experience using Vesalio’s proprietary silicone flow model. Thanks to all physicians and…
As the end of 2019 approaches, we reflect with pride and gratitude on what we achieved: We saw the publication of our First in Man data and initiated our regulatory enabling studies, We received our 2nd CE mark on the expanded #NeVa platform, including designs with more Drop Zones, We organized 5 Vesalio Clot Interaction…
Ljiljana Vilovski, of Bormia Medical was joined by Jessica Koradin, Vesalio’s Clinical Training Specialist in Serbia from Dec 9 to 11. Jessica and Ljiljana met with several stroke teams that are preparing to launch 24 hour/ 7 day services in Serbia.
Another successful VESALIO CLOT INTERACTION WORKSHOP was conducted at the Vall d’Hebron Research Institute on the 18th and 19th of November.
Vesalio and Bormia Med were proud to sponsor the 5th SNSS Meeting in Serbia which took place from 24th to 27th October in Kragujevac.
VESALIO and German distribution partner PRISMA PLUS joined forces to exhibit at the 54th annual neuroRAD conference in Frankfurt, October 9-12, 2019.
VESALIO was proud to be a sponsor of the SLICE 2019 congress conducted in Nice, September 30 to October 2, 2019. Vesalio representatives met with existing and potential NeVa users and discussed their clinical cases.
88 year old female patient presented with a NIHSS of 15. The patient was found on the floor of her bathroom, with left side hemiplegia.
VESALIO was proud to sponsor the ESMINT Society 11th annual meeting in Nice, from 4-6 September 2019.
Right ICA Tip Occlusion 1st Pass Success with “NeVa T” (4.5 x 37 mm) 75 year old female patient presented with NIHSS of 14. Time from Onset was 1,5 hours at the time of admission to Medical Park stroke center. The patient had a medical history of hypertenssion and atrial fibrillation and was on a once/day…
75 year old female patient presented with NIHSS of 19 presented 4 hours after symptom onset. It was noted that the patient had had a knee implant surgery 3 days prior to her stroke. Imaging confirmed distal left MCA occlusion.
81 year old male patient presented with NIHSS of 21. The patient was last seen well 6.5 hours ago. Imaging confirmed Left MCA occlusion.
Vesalio made its exciting debut as an exhibitor at the LINNC congress. Several current users and many physicians interested in NeVa visited the Vesalio exhibit to discuss recently published First-in-Man study data and view the new, highly innovative NeVa designs.
Vesalio announces it has obtained its second CE Approval spanning multiple new NeVa™ product designs and technology. The new generation NeVa devices expand on the Drop Zone™ and Smart Marker™ technologies.
Vesalio announces it has recently raised $5 million in funding. The capital will support the continued global expansion of the NeVa™ Neurothrombectomy System, finance key clinical studies and launch new product introductions.
VESALIO’s™ NeVa attracted interest from the participants from all over the world at the 19th World Live Neurovascular Conference which took place in Barcelona from 1st to 3rd May.
Three successful VESALIO CLOT INTERACTION WORKSHOPs were conducted at the Vall d’Hebron Research Institute on the 24th, 25th and 26th of April. More than 20 attendees from 11 different countries enjoyed the hands-on practice.
A productive meeting with exceptionally experienced NEVA operator, Prof. Serdar Geyik and his team. We performed the drop zone technique on Vesalio’s Flow model and discussed activities at the upcoming WLNC meeting on May 3rd in Barcelona.
On April 5th, the Vassa Medical national sales network convened to celebrate the Italy launch of NeVa at the company’s headquarters in Mirano near Venice. Dr. Massimo Sponza from Udine Hospital was present to train the team on acute ischemic stroke and thrombectomy.
Vesalio announces it has executed multiple exclusive distribution agreements in Europe, Latin America, Asia and the Middle East and now has market coverage in 39 countries for the NeVa™ Neuro-thrombectomy System.
The VESALIO team visited 9 hospitals in Germany during the week of March 11th and spoke to the physicians and stroke teams about their experience with NeVa.
Multiple Swiss stroke centers were visited to review clinical progress with NeVa. Technical discussions ensued with neuro-endovascular physicians regarding the Drop Zone Technique and their positive patient outcomes with NeVa.
From Val D’Isere, France to Honolulu, Vesalio’s early clinical experience data is being presented globally.
Diane Tangun (VP, Market Development – Vesalio) visited Slovenia and Croatia the week of February 4th-8th to work with Igor Bogatec, Vedran Brajković and Klemen Janežič visiting key NeVa accounts. There was excellent interaction with NeVa physician operators on recent cases in addition to finalizing 2019 plans for NeVa development in the region. Vesalio is…
On January 18, 2019, Professor Serdar Geyik (Istanbul Istinye University) presented his early NeVa experience at the ABC-WIN Seminar in Val D’Isere, France.
On January 18 a NeVa flow model workshop was conducted at the Warsaw Military Medical Institute where the interventional radiology team is headed by Dr. Piotr Piasecki.
Vesalio and PrismaPlus team members gathered in Frankfurt, Germany on January 15 to discuss marketing plans for the new year. NeVa clinical initiatives and new product introductions were reviewed to build on 2018 achievements in Germany.
Vesalio’s NeVa™ neurothrombectomy product line was featured at a 3-day course (JAN 9-11, 2019) entitled “Endovascular Treatment of Ischemic Strokes” in Warsaw, Poland.
In December 2018 Vesalio™ members Diane Tangun and William von Brendel joined Mermaid Medical for a 2018 Business Review and 2019 Planning Session.
Seasons Greetings to acute stroke teams and all those that take part in the treatment of stroke patients around the world!
Another successful VESALIO Stroke Revascularization Laboratory was conducted at the Vall d’Hebron Research Institute on the 6th and 7th of November with 12 attendees from 4 different countries.
VESALIO’s™ Mechanical Thrombectomy Stent Retriever attracted the interest we anticipated at our first SLICE symposium. Physicians test drove NeVa products and discovered the distinct design engineered to improve first pass success with all clot types.
Vesalio announces it has initiated the full commercial European launch of its NeVa neurothrombectomy platform at the 10th annual congress of the European Society of Minimally Invasive Neurological Therapy.
A tough case with huge clot burden from Dr Vladimir Kalousek! Carotid T, huge clot burden and from what I hear, a rather tortuous, difficult anatomy NeVa M1 saves the day with a TICI 3 in a single pass!
We had an amazing and fun training with our European team using the NEVA TRANKENSTEIN flow model with Dr Arthur Grigorian and Professor Istvan Szikora at the National Institute of Clinical Neurosciences, Budapest.
Great meeting with the team of University Hospital of REIMS today who have done their 3rd NeVa case. Vesalio is honored to count Prof Laurent PIEROT and his team among NeVa’s initial users.
Another successful Vesalio Stroke Revascularization Laboratory was conducted in Barcelona on June 28. VESALIO would like to express its gratitude to Professor Juan Macho and Dr. Marc Ribo for their support and proctoring.
Vesalio announces it has executed multiple exclusive distribution agreements in Europe and now has market coverage in 25 countries for the NeVa Neurothrombectomy System.
Vesalio announces it has completed European enrollment of the first twenty-five human cases in a post-market registry of the proprietary NeVa™ neurothrombectomy platform for the treatment of stroke.
Vesalio announces the CE Mark certification of its first product line, the proprietary NeVa™ neurothrombectomy platform for the treatment of stroke.
